Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.
Follow VRTX
Vertex Pharmaceuticals Incorporated (VRTX) Operating cash flow
Vertex Pharmaceuticals Incorporated's operating cash flow for fiscal 2025 was $3.6B, compared with −$492.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.3B. Over the past ten years it has ranged from −$492.6M (fiscal 2024) to $4.1B (fiscal 2022); the current reading is higher than 91% of that period. Vertex Pharmaceuticals Incorporated ranks 2nd of 611 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $3.6B | — |
| FY2024 | −$492.6M | — |
| FY2023 | $3.5B | (14.35%) |
| FY2022 | $4.1B | 56.23% |
| FY2021 | $2.6B | (18.75%) |
| FY2020 | $3.3B | 107.32% |
| FY2019 | $1.6B | 23.54% |
| FY2018 | $1.3B | 50.34% |
| FY2017 | $844.9M | 257.87% |
| FY2016 | $236.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $1.1B | (21.20%) |
| Mar 2026 | $1.4B | 186.77% |
| Dec 2025 | $498.0M | (59.88%) |
| Sep 2025 | $1.2B | 15.68% |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $4.7B |
| VRTX Vertex Pharmaceuticals Incorporated | $4.3B |
| RPRX Royalty Pharma PLC compare | $3.0B |
| ARGX argenex SE compare | $1.6B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.5B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $911.8M |
| ROIV Roivant Sciences Ltd. compare | −$816.5M |
| MRNA Moderna, Inc. compare | −$1.1B |
| RVMD Revolution Medicines, Inc. compare | −$1.2B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on VRTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement